Astorg

🌍 𝗔𝘀𝘁𝗼𝗿𝗴 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗗𝗮𝘆 𝟮𝟬𝟮𝟲 | 𝗧𝗵𝗶𝗿𝗱 𝗘𝗱𝗶𝘁𝗶𝗼𝗻   Last week in Paris, we brought together LPs, portfolio company representatives, external experts and Astorg team members for a full day of substantive dialogue on sustainability and long-term value creation in private equity.   Because at Astorg, sustainability is about building stronger and better businesses, by embedding it into strategy, operations and governance. We help our portfolio companies to anticipate change, differentiate in their markets and turn sustainability into a genuine competitive advantage.   💡𝗧𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝘄𝗲𝗿𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗲𝗱 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴, 𝘁𝗼𝗽𝗶𝗰𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱: ➤ ESG integration across M&A and portfolio operations ➤ Responsible AI and data transparency ➤ Biodiversity and nature-related risks ➤ Upcoming forced labour regulations ➤ real-world case studies from Solabia Group, Corialis Group, Corden Pharma - A Full-Service CDMO, Normec and IPCOM.   Our live polls reflected where the industry's attention is moving: climate adaptation, responsible AI and regulatory readiness are rising sharply on leadership agendas. And sustainability is increasingly being recognised - by clients, investors and management teams alike - as a driver of differentiation and revenue growth, not just risk mitigation.   🙏 Thank you to everyone who joined and contributed. These conversations matter, and they are getting sharper every year.   #Sustainability #ValueCreation #ResponsibleAI #Biodiversity #Focus #Performance #Partnership Viviana Occhionorelli | Nathalie Medawar | Alexandre Dussaucy | Corinne Schreiber | Hakim Smires Bennani | Chiara M. | Michel Sudol | Marco Zomer | André Durrer | Lien Van den Broeck | Evi Desmet | Roselien De Clercq | Eva Rossie | Luc De Busscher | Laurent LASSALLE | Nicole Sherwin | Sibylle Chauveau Lamy | Katja Wachter

🤝 𝗜𝘁’𝘀 𝗮𝗻 𝗔𝘀𝘁𝗼𝗿𝗴 𝗗𝗲𝗮𝗹! Astorg is pleased to share that it has entered into an agreement to acquire a majority stake in Groupe BARKENE, a leading multi-specialist B2B technical services platform in France, operating across electronic security, fire safety, automatic doors and remote monitoring. Barkene’s management team will significantly reinvest alongside Astorg, showing strong alignment and a shared ambition for the next phase of development. This transaction was agreed on a pre-emptive basis, reflecting our proactive sourcing approach and deep sector expertise. Founded in 2018 by Richard Weihart and backed by Montefiore Investment, Barkene has built a differentiated platform combining technical expertise, operational excellence and strong local footprint with national scale and a high level of recurring, service-driven activity. The company has executed a strong buy-and-build strategy – completing and integrating 16 strategic acquisitions across France and reaching over €110 million in revenue in 2025.       🎯 𝗢𝘂𝗿 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝗻 𝗶𝘀 𝗰𝗹𝗲𝗮𝗿: ➤ Accelerating consolidation in a fragmented market ➤ Strengthening the platform’s national footprint ➤ Enhancing operational performance and capturing scale benefits                  This transaction also underscores the strong momentum of our Mid-Cap strategy with three investments completed across Europe in the past nine months. Our multi-local reach, sector focus and recent team strengthening - notably in France - are key to sourcing and executing high-quality proprietary opportunities. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁: https://lnkd.in/edrkC97U Lionel de Posson | Jérôme Triebel | Valentin Dolla | Augustin Bolze | Camille Duiquet #BusinessServices #Dealmaking #Expansion #MergerandAcqusition #Focus #Performance #Patnership

🎯 𝗖𝗹𝗮𝗿𝗶𝗼 𝗘𝘅𝗶𝘁 𝗖𝗹𝗼𝘀𝗲𝗱 | 𝗢𝗻𝗲 𝗖𝗹𝗲𝗮𝗿 𝗧𝗵𝗲𝘀𝗶𝘀 | $𝟮𝗯𝗻+ 𝗥𝗲𝘁𝘂𝗿𝗻𝗲𝗱 𝘁𝗼 𝗟𝗣𝘀 We've closed our exit from Clario, following its acquisition by Thermo Fisher Scientific. This $9.4b transaction represents the largest full healthcare PE exit announced globally in 2025. Since our investment, we partnered with Christopher Fikry, M.D. and the Clario management team to execute a focused transformation: turning a series of point solutions into the global leading endpoint capture platform. 📈 Over the holding period, the business more than doubled its revenue and EBITDA, through organic growth, a large-scale technology transformation, six acquisitions, and two non-core divestitures. This is what hands-on partnership with management looks like in practice. Our thesis was clear from the outset - back a high-quality, niche healthcare platform and scale it into a global leader. Clario is today a scaled, differentiated business at the core of clinical development, enabling more data-driven and efficient clinical trials worldwide. A conviction only possible through Astorg's deep healthcare expertise and long-term understanding of the sector. This exit reflects Astorg's long-standing approach: genuine partnership with management, deep healthcare expertise, and disciplined value creation - even in selective market conditions. 🤝We thank Christopher Fikry, M.D. and the entire Clario leadership team for the outstanding partnership and wish them continued success in their next phase of growth with Thermo Fisher Scientific. Proud of what the team built. More to come. #Healthcare #SectorExpertise #LifeSciences #ClinicalTrials #ValueCreation #Exit #Focus #Performance #Partnership

📰 Judith Charpentier 𝗻𝗮𝗺𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗪𝗮𝗹𝗹 𝗦𝘁𝗿𝗲𝗲𝘁 𝗝𝗼𝘂𝗿𝗻𝗮𝗹’𝘀 𝟮𝟬𝟮𝟲 “𝗪𝗼𝗺𝗲𝗻 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵” 𝗟𝗶𝘀𝘁 We are proud to share that Judith Charpentier, Co-Managing Partner at Astorg and Co-Head of the Flagship Fund, has been named to the 2026 “Women to Watch in Private Equity” list by the The Wall Street Journal Pro. Published annually, this list recognizes a select group of senior dealmakers whose leadership, investment judgement and strategic vision are helping shape the future of the industry. At Astorg, Judith plays a central role in the firm’s leadership and investment strategy. Over the years, she has also built 𝗼𝗻𝗲 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲’𝘀 𝗺𝗼𝘀𝘁 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘀𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗳𝗿𝗮𝗻𝗰𝗵𝗶𝘀𝗲𝘀 - with more than €6.5 billion deployed across pharmaceutical services and technology, MedTech, life-science tools and diagnostics. As Judith puts it: “𝗙𝗼𝗰𝘂𝘀 𝗮𝗻𝗱 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗿𝗲 𝗳𝗮𝗿 𝗺𝗼𝗿𝗲 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝘁𝗵𝗮𝗻 𝘁𝗿𝘆𝗶𝗻𝗴 𝘁𝗼 𝗰𝗼𝘃𝗲𝗿 𝗲𝘃𝗲𝗿𝘆𝘁𝗵𝗶𝗻𝗴. 𝗕𝘆 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗱𝗲𝗲𝗽 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗶𝗻 𝘀𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘀𝘂𝗯𝘀𝗲𝗰𝘁𝗼𝗿𝘀, 𝘆𝗼𝘂 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗶𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝗻𝗲𝗲𝗱𝗲𝗱 𝘁𝗼 𝘁𝗿𝘂𝗹𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀𝗲𝘀 𝗮𝗻𝗱 𝘀𝗰𝗮𝗹𝗲 𝘁𝗵𝗲𝗺 𝗶𝗻𝘁𝗼 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗹𝗲𝗮𝗱𝗲𝗿𝘀.” This mindset has helped shape landmark investments including Clario, Corden Pharma - A Full-Service CDMO, Cytel, Echosens, HRA Pharma, Nexpring Health and contributed to one of the largest private-equity exits of 2025 with the $9.4bn sale of Clario to Thermo Fisher Scientific. Beyond dealmaking, Judith plays an important role in shaping Astorg’s leadership and mentoring the next generation of investors, reflecting the partnership culture and the entrepreneurial spirit at the heart of the firm. As she notes: “Private Equity is fundamentally a people business – relationships and trust are critical”. Coming just after International Women’s Day, this recognition also highlights the importance of continuing to broaden representation across our industry and encouraging more leaders to emerge and thrive. 👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝟮𝟬𝟮𝟲 𝗪𝗼𝗺𝗲𝗻 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵 𝗟𝗶𝘀𝘁 𝘃𝗶𝗮 𝗪𝗦𝗝 𝗣𝗿𝗼 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗘𝗾𝘂𝗶𝘁𝘆: https://lnkd.in/e2ue8jMQ #WomenToWatch #WSJ #Healthcare #Leadership #ValueCreation #Talent #EntrepreunarialCulture #Focus #Performance #Partnership

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀   Astorg is pleased to share that its portfolio company Solabia Group has signed definitive agreements to acquire three complementary businesses across natural active ingredients and diagnostics:   ➤ Mibelle Biochemistry (Switzerland) – science-backed natural actives with proprietary plant stem cell technology. Mibelle is a strategic and transformative addition, strengthening Solabia’s leadership in natural active ingredients. ➤SEQENS’ Botanical Actives and In-Vitro Diagnostics Activity (France) – reinforcing botanical capabilities and securing critical supply ➤ Xebios Diagnostics Group (Germany & Netherlands) – expanding diagnostics scale and innovation capacity    These are Solabia’s first acquisitions since our investment in October 2025 - accelerating a focused buy-and-build strategy rooted in deep sector expertise and close partnership with management.   Natural active ingredients, particularly biotech-based, represent a compelling consolidation terrain. The market is fragmented, demand is resilient and structural drivers across beauty, wellness and scientifically validated solutions are strong. This is exactly where our model performs best.   At Astorg, buy-and-build is a long-standing core capability. For decades, we have scaled specialist platforms through disciplined M&A, combining sector expertise, rigorous underwriting, proactive origination and structured integration to turn fragmentation into strategic advantage.   Together, these acquisitions accelerate Solabia’s international footprint, broaden its scientific and innovation capabilities, and reinforce its position as a leading independent biotechnology platform.   🎯 𝗧𝗵𝗲 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝗻 𝗶𝘀 𝗰𝗹𝗲𝗮𝗿: accelerate consolidation and shape a global category leader, delivering durable, long-term performance.   👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/eAT3CD5V   #Healthcare #Biotechnology #SectorSpecialisation #Growth #InternationalExpansion #ValueCreation #BuyAndBuild #MandA #Focus #Performance #Partnership Nicolas Marien/Paul Arhanchiague/Louis Jouglard/Jean-Baptiste Dellon/Francois-Xavier QUENIN/Francois Pointurier/Mathieu Pinault

🏛 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗦𝘂𝗺𝗺𝗶𝘁 | 𝗟𝗼𝗻𝗱𝗼𝗻 𝟮𝟬𝟮𝟲   This week, Astorg joined senior leaders from across private markets at the European Private Capital Summit in London - a gathering of 350+ GPs, LPs and advisors. Two panel conversations stood out - both anchored in what we believe drives durable value creation: 𝗱𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗲 𝗮𝗻𝗱 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻. 🔎 𝗘𝘅𝗶𝘁 𝗥𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗼𝗽𝘁𝗶𝗼𝗻𝗮𝗹𝗶𝘁𝘆 𝗲𝗮𝗿𝗹𝘆 🎙️Keith Beattie, Head of Operations explained: “Exit readiness is the natural result of disciplined value creation. When governance, performance and strategic alignment are embedded early, you create optionality - and the ability to exit from a position of strength”   🤖 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜: 𝗳𝗿𝗼𝗺 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗜𝗺𝗽𝗮𝗰𝘁 🎙️Valerie Legat, Head of Digital: “GenAI is redefining how portfolio companies design products, deliver value and compete. We’re supporting our portfolio companies to integrate AI and equipping teams with the capabilities to turn innovation into sustained competitive advantage.” 🙏 Thank you to CapLink Group, the moderators and fellow panelists for these insightful discussions. Paul Reading | Alisha Peterle | Rob Mangan | Thomas Dixon | Carrie Osman | Raj Bakhru, CFA, CISSP | Cameron Hulett | Jesse Thomas | Brian Mason | Mittu Sridhara #ValueCreation #ExitReadiness #GenerativeAI #PortfolioPerformance #DigitalTransformation #Focus #Performance #Partnership

🌍 𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗗𝗲𝗰𝗮𝗿𝗯𝗼𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝘁𝗼 𝗮 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗗𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗲   At Astorg, performance starts with discipline - in how we invest, how we partner with management teams, and how we build and transform businesses for the long term. That same mindset applies to decarbonization.   🎯 Today, 𝟴𝟴% 𝗼𝗳 𝗼𝘂𝗿 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 (by invested capital) has validated science-based targets - well ahead of our 2025 commitment. It places us among the most advanced in our space and reinforces our focus on disciplined execution.   But this isn’t about targets alone. It’s about embedding climate into execution: ➤ Integrating it into diligence and governance ➤ Translating data into operational priorities ➤ Working hands-on with management teams to drive measurable outcomes   In a recent Op-Ed, Viviana Occhionorelli, Head of Sustainability, shares concrete examples from across our portfolio - showing how climate ambition becomes operational discipline, delivering efficiency gains, commercial differentiation, and stronger positioning with customers.   Because when decarbonization is treated as a performance discipline, it creates value now and over the long term.   👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗢𝗽-𝗘𝗱 𝗼𝗻 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲: https://lnkd.in/eN8beVfa   #ValueCreation #Sustainability #Decarbonization #SBTI #Focus #Performance #Partnership

🚀 𝟮𝟬𝟮𝟲 𝗣𝗿𝗼𝗺𝗼𝘁𝗶𝗼𝗻𝘀 𝗨𝗻𝘃𝗲𝗶𝗹𝗲𝗱 We’re proud to announce a new round of promotions across Astorg in 2026. Among them: 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗧𝗲𝗮𝗺 ➤ Adrien Celdran, promoted to Managing Director ➤ Desislava Nikolov, promoted to Director ➤ Giovanni Paolo Turri Turri, promoted to Investment Manager ➤ Mélodie Valentin Melard Mélard, promoted to Associate 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗧𝗲𝗮𝗺 ➤ Stijn C., promoted to Head of Corporate Legal ➤ Sofia Drakou, promoted to Senior Legal Counsel These promotions are part of a broader wave of internal progress across Astorg’s investment, business development and corporate teams. Talent development is core to our culture because our people are at the heart of what we do. Trust, high standards, impact recognition, and room to grow enable them to perform at their best and build long-term value together. 👏Congratulations to all those promoted this year. The journey continues.  #People #Talent #EntrepreneurialCulture #Focus #Performance #Partnership

✨ 𝗪𝗶𝘁𝗵 𝘁𝗵𝗮𝗻𝗸𝘀, 𝗮𝘀 𝘄𝗲 𝗰𝗹𝗼𝘀𝗲 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿 As the year comes to a close, we thank our Limited Partners, portfolio company management teams, advisors and broader network. Built on trust and long-term partnership, our collective journey - and what we achieved together in 2025 - continues to shape how we create value and grow. Wishing you a peaceful season, and looking ahead to 2026 with shared ambition. ✨ #LongTermValue #SharedJourney #Growth #Focus #Performance #Partnership #Trust

🏛 𝗣𝗘𝗜 𝗪𝗼𝗺𝗲𝗻 𝗶𝗻 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗠𝗮𝗿𝗸𝗲𝘁𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 | 𝗟𝗼𝗻𝗱𝗼𝗻 𝟮𝟬𝟮𝟱   Last week, Keith Beattie, Partner & Head of Operations at Astorg, joined industry peers at Private Equity International’s Women in Private Markets Summit - an event that brought together more than 800 investors, fund managers and thought leaders shaping the future of private markets. Keith Beattie spoke on the panel “𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗖𝗮𝗿𝘃𝗲-𝗢𝘂𝘁𝘀: 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀, 𝗥𝗶𝘀𝗸𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀”, alongside Isabelle Pagnotta, Kathryn Pothier and Andrew Nikou. 💡 𝗞𝗲𝘆 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻: ➤ 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗯𝗲𝘆𝗼𝗻𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝘆𝗰𝗹𝗲𝘀. Carve-out pipelines are shaped less by macro conditions than by sector specialisation, insight, and trusted relationships. Astorg’s deep sub-sector expertise enables bilateral conversations and early access to overlooked assets. ➤ 𝗪𝗶𝗻𝗻𝗶𝗻𝗴 𝗶𝗻 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝘀. Creativity, credibility, and partnership are decisive. Bilateral engagement reduces auction risk, while Astorg’s specialist operations and carve-out track record support fast, high-conviction execution. ➤ 𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗶𝗻𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲. Carve-outs often reveal hidden value - the “jewel” inside large organisations. Astorg’s model is built around designing value-creation plans pre-signing, knowing exactly where value sits, and moving decisively where others see operational complexity. ➤ 𝗪𝗵𝗮𝘁 𝗱𝗲𝗳𝗶𝗻𝗲𝘀 𝗮 𝘀𝘁𝗮𝗻𝗱𝗼𝘂𝘁 𝗰𝗮𝗿𝘃𝗲-𝗼𝘂𝘁. Precision and strategic clarity are essential. The strongest carve-outs emerge with a sharper identity and a long-term growth blueprint - as illustrated by Astorg portfolio companies @Nexpring Health and @Fastmarkets, two carve-outs where a well-defined thesis translated into standalone leaders. 🎙 Keith Beattie: “For Astorg, carve-outs are a natural expression of our specialisation and conviction. We turn complexity into opportunity by knowing where the value lies and by partnering closely with management teams to build focused, high-performing businesses with long-term potential.” 🙏 Hannah Ogunlowo and Jessica Woolls from Private Equity International #Focus #Performance #Partnership #ValueCreation #Concivtion #CarveOuts #Specialisation #OperationalExcellence #Leadership